Fu-Shun Yen - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Fu-Shun Yen

Showing results (81-90 of 101) with videos related to

Pageof 11

Sort By:

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 18, 2023

Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 DiabetesFu-Shun Yen, Ming-Chih Hou, James Cheng-Chung Wei, et al.

Diabetes Research and Clinical Practice|June 18, 2025

Comparative outcomes of adding SGLT2 inhibitors versus incretin-based therapies to insulin in type 2 diabetesFu-Shun Yen, James Cheng-Chung Wei, Yu-Han Huang, et al.

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 22, 2025

The impact of sodium-glucose cotransporter-2 inhibitors on dialysis risk and mortality in kidney transplant patients with diabetesFu-Shun Yen, Chih-Cheng Hsu, Yun-Kai Yeh, et al.

Pharmaceuticals (Basel, Switzerland)|September 27, 2025

Impact of Adding GLP-1 Receptor Agonists to Insulin Therapy on Cardiovascular and Microvascular Outcomes in Type 2 Diabetes: A Nationwide Cohort Study from TaiwanFu-Shun Yen, James Cheng-Chung Wei, Chen-Yu Sung, et al.

Annals of the American Thoracic Society|February 12, 2025

SGLT-2 Inhibitors and the Risk of Chronic Obstructive Pulmonary Disease Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease PatientsFu-Shun Yen, James Cheng-Chung Wei, Yu-Han Huang, et al.

Frontiers in Immunology|April 9, 2026

Metformin use and the risk of incident immune-mediated diseases in patients with type 2 diabetes: a population-based cohort studyQianru Zhang, Fu-Shun Yen, Chuanhui Xu, et al.

Diabetes Research and Clinical Practice|April 14, 2025

Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patientsFu-Shun Yen, James Cheng-Chung Wei, Chen Wang, et al.

Diabetes, Obesity & Metabolism|August 30, 2024

Microvascular disease and its association with dementia in patients with type 2 diabetes: A nationwide cohort study in TaiwanYu-Hsin Yen, Fu-Shun Yen, Fu-Shun Ko, et al.

Diabetes, Obesity & Metabolism|December 9, 2025

Journal of the Royal Society of Medicine|November 3, 2025

SGLT2 inhibitors for primary prevention of macrovascular and major microvascular complications in type 2 diabetes: an island-wide cohort studyWan-Yin Cheng, Fu-Shun Yen, Yao-Min Hung, et al.

Pageof 11

Search research articles

Showing results (81-90 of 101) with videos related to

Sort By:

Pageof 11

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 18, 2023

Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 DiabetesFu-Shun Yen, Ming-Chih Hou, James Cheng-Chung Wei, et al.

Diabetes Research and Clinical Practice|June 18, 2025

Comparative outcomes of adding SGLT2 inhibitors versus incretin-based therapies to insulin in type 2 diabetesFu-Shun Yen, James Cheng-Chung Wei, Yu-Han Huang, et al.

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 22, 2025

The impact of sodium-glucose cotransporter-2 inhibitors on dialysis risk and mortality in kidney transplant patients with diabetesFu-Shun Yen, Chih-Cheng Hsu, Yun-Kai Yeh, et al.

Pharmaceuticals (Basel, Switzerland)|September 27, 2025

Annals of the American Thoracic Society|February 12, 2025

Frontiers in Immunology|April 9, 2026

Metformin use and the risk of incident immune-mediated diseases in patients with type 2 diabetes: a population-based cohort studyQianru Zhang, Fu-Shun Yen, Chuanhui Xu, et al.

Diabetes Research and Clinical Practice|April 14, 2025

Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patientsFu-Shun Yen, James Cheng-Chung Wei, Chen Wang, et al.

Diabetes, Obesity & Metabolism|August 30, 2024

Microvascular disease and its association with dementia in patients with type 2 diabetes: A nationwide cohort study in TaiwanYu-Hsin Yen, Fu-Shun Yen, Fu-Shun Ko, et al.

Diabetes, Obesity & Metabolism|December 9, 2025

Journal of the Royal Society of Medicine|November 3, 2025

SGLT2 inhibitors for primary prevention of macrovascular and major microvascular complications in type 2 diabetes: an island-wide cohort studyWan-Yin Cheng, Fu-Shun Yen, Yao-Min Hung, et al.

Pageof 11